Improving decision-making for lung cancer treatment
Official title: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial
Run by Mayo Clinic · NCT06122064 · Data updated 2026-11-12
This study is testing a new communication tool to see if it helps patients with non-small cell lung cancer feel more satisfied and confident in their treatment choices when talking with their doctors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | November 20, 2023 |
| Main results expected | October 31, 2029 |
| Study ends | October 31, 2029 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT06122064 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult patients aged 18 and older with stage II or higher non-small cell lung cancer who are eligible for adjuvant treatment.
✕Probably not a fit
Patients with significant barriers to informed consent or shared decision-making, such as dementia or severe sensory impairments, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates a shared decision-making communication tool designed to enhance the quality of treatment discussions between patients with non-small cell lung cancer and their clinicians. Patients are randomized into two groups: one receiving standard care and the other using the decision-making tool during their clinical encounters. The study aims to assess improvements in patient satisfaction and reductions in decisional conflict regarding treatment choices. Follow-up assessments will occur at 2 and 6 weeks post-intervention to evaluate the effectiveness of the tool.
Why it matters
Potential benefit: If successful, this approach could lead to better-informed patients and improved satisfaction with treatment decisions.
How similar studies have gone: Previous studies have shown that shared decision-making tools can enhance patient satisfaction and decision quality, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * CLINICIANS: * All clinicians within identified departments participating are eligible (doctor of medicine \[MD\]/doctor of osteopathy \[DO\], fellows/residents, physician assistant \[PA\]/nurse practitioner \[NP\]) * PATIENTS: * Adult patients (\>= 18 years of age) * Appointments at Mayo Clinic in Rochester * Non-small cell lung cancer (NSCLC) stage \> 1B * Eligible by their oncologist for adjuvant treatment Exclusion Criteria: * Exclude patient with major barriers to provide written informed consent or to participate in shared decision-making (i.e., dementia, severe hearing or visual impairment)
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Konstantinos Leventakos, M.D., Ph.D. — Mayo Clinic in Rochester
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Yoga intervention to improve physical performance and quality of life for cancer patients and their caregivers
This study tests whether a yoga program can help improve physical performance and quality of life for cancer patients and their caregivers during radiotherapy.
-
Exploring gut microbiome and fecal transplant effects on GI issues in cancer patients
This study is testing how the gut bacteria affect stomach issues in cancer patients receiving certain treatments and whether a stool transplant can help relieve those problems.
-
Surgical order of blood vessel division and circulating tumor DNA after lung cancer surgery
This compares doing the pulmonary vein first versus the pulmonary artery first during lung cancer surgery to see if it lowers circulating tumor DNA in adults with stage I–III non-small cell lung cancer.
-
Morning versus afternoon immunotherapy for advanced or metastatic solid tumors
This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.
-
SX-682 with Atezolizumab for advanced or metastatic NSCLC
This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.
-
Using blood and tissue biomarkers to guide immunotherapy and later treatment choices in advanced non-small cell lung cancer
This trial tests whether blood and tumor biomarkers can predict who will respond to first-line PD‑1/PD‑L1 immunotherapy and help pick better second-line treatments for people with stage IIIB–IV non‑small cell lung cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.